Nautilus Biotechnolgy (NAUT) Stock Statistics & Valuation Metrics

Nautilus Biotechnolgy has a market cap or net worth of $95.62M. The enterprise value is $111.92M.

Nautilus Biotechnolgy has 126,148,470 shares outstanding. The number of shares has decreased by -2.65% in one year.

Nautilus Biotechnolgy’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is 0.00%.

The current PE Ratio of Nautilus Biotechnolgy is -2.98. Nautilus Biotechnolgy’s PEG ratio is -0.30.

In the last 12 months, Nautilus Biotechnolgy had revenue of 0.00 and earned -70.78M in profits. Earnings per share was -0.56.

In the last 12 months, operating cash flow was -59.14M and capital expenditures -2.12M, giving a free cash flow of -61.27M billion.

Nautilus Biotechnolgy pays an annual dividend of ―, resulting in a dividend yield of ―

Nautilus Biotechnolgy upcoming earnings date is Apr 29, 2025, TBA Not Confirmed.

Nautilus Biotechnolgy as a current ratio of 17.40, with Debt / Equity ratio of 14.60%

In the past 12 months, Nautilus Biotechnolgy has paid 0.00 in taxes.

Nautilus Biotechnolgy EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -3.49.

Nautilus Biotechnolgy has $129.89M in cash and marketable securities with $33.62M in debt, giving a net cash position of -$99.42M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Nautilus Biotechnolgy is $2.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy